Aiming at early-stage vulnerable plaques:A nanoplatform with dual-mode imaging and lipid-inflammation integrated regulation for atherosclerotic theranostics  

作　　者：Yao Wang Zhebin Chen Qiongjun Zhu Zhezhe Chen Guosheng Fu Boxuan Ma Wenbin Zhang 

机构地区：[1]Department of Cardiology,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,Hangzhou,China [2]Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province,Hangzhou,China

出　　处：《Bioactive Materials》2024年第7期94-105,共12页生物活性材料（英文）

基　　金：supported by National Natural Science Foundation of China (No.32201128,No.82270262,and No.82070408);Zhejiang TCM Science and Technology Program TCM modernization Special project,China (No.2022ZX012).

摘　　要：The vulnerable plaques in atherosclerosis can cause severe outcome with great danger of acute cardiovascular events.Thus,timely diagnosis and treatment of vulnerable plaques in early stage can effectively benefit the clinical management of atherosclerosis.In this work,a targeting theranostic strategy on early-stage vulnerable plaques in atherosclerosis is realized by a LAID nanoplatform with X-CT and fluorescent dual-mode imaging and lipid-inflammation integrated regulation abilities.The iodinated contrast agents(ICA),phenylboronic acid modified astaxanthin and oxidized-dextran(oxDEX)jointly construct the nanoparticles loaded with the lipid-specific probe LFP.LAID indicates an active targeting to plaques along with the dual-responsive disassembly in oxidative stress and acidic microenvironment of atherosclerosis.The X-CT signals of ICA execute the location of early-stage plaques,while the LFP combines with lipid cores and realizes the recognition of vulnerable plaques.Meanwhile,the treatment based on astaxanthin is performed for restraining the progression of plaques.Transcriptome sequencing suggests that LAID can inhibit the lipid uptake and block NF-κB pathway,which synergistically demonstrates a lipid-inflammation integrated regulation to suppression the plaques growing.The in vivo investigations suggest that LAID delivers a favorable theranostics to the early-stage vulnerable plaques,which provides an impressive prospect for reducing the adverse prognosis of atherosclerosis.

关 键 词：Atherosclerosis THERANOSTICS Nanoplatform Dual-mode imaging Lipid-inflammation integrated regulation 

分 类 号：R543.5[医药卫生—心血管疾病]